Genpact (G): Assessing Valuation Following Launch of AI-Driven Insurance Policy Suite Powered by Microsoft Azure AI

Simply Wall St

Genpact (NYSE:G) just rolled out its Genpact Insurance Policy Suite, tapping into Microsoft Azure AI to power a new wave of automation in commercial and specialty insurance. This suite aims to cut administrative cycle times by up to 75%, while boosting underwriting capacity with more touchless processing and streamlined decision support. For investors, this kind of product launch signals Genpact’s ambitions to be a force in agentic AI for the insurance sector, a space that is primed for digital transformation.

The announcement comes as Genpact’s stock has moved upward over the past twelve months, with a 10% return, even as its momentum had slowed in recent months. Year to date, shares have dipped slightly, and in the past month the price has pulled back by 7%. This new AI product could re-invigorate growth expectations, especially following a period where the company’s headline numbers have not made big waves. That makes today’s move feel like a real pivot point for the stock narrative.

After a year of steady gains and fresh innovation in its pipeline, does Genpact offer investors real upside from here, or have markets already priced in a future shaped by AI-driven growth?

Most Popular Narrative: 19.5% Undervalued

According to the most widely followed narrative, Genpact is trading below its estimated fair value, with significant room for upside if expectations are met.

“Accelerated client adoption of Genpact's Advanced Technology Solutions, particularly in data and AI, should drive higher growth and improved margins. These offerings deliver over twice the revenue per headcount compared to legacy services and are expanding at over twice the company's overall rate. This points toward robust long-term revenue and margin expansion.”

Curious about what’s fueling this bullish price target? The secret ingredient is a bold forecast for future earnings and profit margins, with numbers rarely seen outside of high-growth sectors. The narrative hinges on a mix of ambitious growth assumptions and a forward-looking valuation multiple. Want to see how these projected leaps in value could push Genpact’s stock far beyond today’s levels? The details will surprise you.

Result: Fair Value of $52.44 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, decelerating legacy business growth and challenging macroeconomic conditions could still threaten Genpact’s ability to fully deliver on these bullish projections.

Find out about the key risks to this Genpact narrative.

Another View: What Does Our DCF Model Say?

Stepping back from analyst price targets, the SWS DCF model performs a detailed analysis of Genpact’s future cash flows and signals significant undervaluation. Could Genpact’s long-term fundamentals be more important than short-term expectations?

Look into how the SWS DCF model arrives at its fair value.

G Discounted Cash Flow as at Sep 2025

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Genpact for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Genpact Narrative

If you’re not convinced by these perspectives or simply want to dig deeper into the numbers, you can craft your own story in under three minutes, your way. Do it your way.

A great starting point for your Genpact research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Investment Opportunities?

Broaden your strategy and sharpen your portfolio by tapping into market shifts now. The right tools put you one step ahead of tomorrow’s winners. Don’t let the best ideas pass you by.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Genpact might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com